News

Artificial enzymes programmed to destroy SARS-CoV-2

Cambridge scientists have used synthetic biology to create artificial enzymes programmed to target the genetic code of SARS-CoV-2 and destroy the virus.

Molecular Pathology & Genomics

Genes identified to potentially diagnose Lyme disease

Researchers at the Icahn School of Medicine at Mount Sinai in New York have identified 35 genes that are particularly highly expressed in people with long-term Lyme disease.

Haematology & Transfusion Science

How stealthy HIV evades drugs and immunity

An immune response that likely evolved to help fight infections appears to be the mechanism that drives human immunodeficiency virus (HIV) into a latent state, researchers at Duke Health in the US report.

Microbiology & Virology

Tech news: December 2022

Maine Standards

Documentation Platforms

Microbiology & Virology

Bone marrow organoids

This technology will allow for the screening of multiple anti-cancer drugs at the same time, as well as testing personalised treatments for individual cancer patients.

Microbiology & Virology

Under the microscope: Photoacoustic microscopy

What is photoacoustic microscopy?

Molecular Pathology & Genomics

Novel device to measure nerve activity

The device, described in an article in Scientific Reports, has potential applications for supporting more personalised treatments for sepsis and mental health conditions, such as

Data-driven learning health systems

The call comes as a new report from Health Data Research UK (HDR UK) and the Health Foundation warns that tackling the huge pressures currently faced by health and care services as a resu

Microbiology & Virology

Skin susceptibility to diseases

Emanual Maverakis, Professor of Dermatology, Molecular Medical Microbiology at UC Davis, said: “Different skin characteristics at different body sites may affect the skin’s susceptibility

Microbiology & Virology

Under the microscope: lecanemab

What is lecanemab?

It is a drug that is hoped to slow Alzheimer’s disease, which has been developed by the pharma companies Eisai and Biogen.

Immunology

Cell-free DNA cancer detection

Their work highlights an approach that offers more than 12-fold cost-savings over conventional methods to sequence cfDNA methylome, along with a computational model to extract information

Molecular Pathology & Genomics
Top